Medicine and Dentistry
Assessment of Humans
33%
Bacterial Vaginosis
33%
Biological Marker
66%
Bladder
14%
Cervix
18%
Childbirth
11%
Clinical Examination
33%
Cohort Analysis
33%
Congestive Heart Failure
33%
Disease Course
33%
Diseases
29%
Dysbiosis
9%
Facial Expression
11%
Feces
16%
Fetal Heart
33%
Fetus Echography
13%
Gene Sequence
13%
Gestational Diabetes
33%
Gut Microbiota
16%
Gynecological Examination
13%
Heart Tumor
25%
ICIQ (Incontinence)
42%
Imaging Technique
33%
Incontinence
15%
Isoflavone Derivative
33%
Magnetic Resonance Imaging
33%
Microbiome
33%
Muscle Disease
22%
Overactive Bladder
33%
Pain
33%
Papule
11%
Pelvic Organ Prolapse
30%
Pelvis
23%
Placebo
33%
Porphyromonas
11%
Postmenopause
33%
Prevotella
11%
Progeny
33%
Prolapse
30%
Quality of Life
13%
Rapamycin
33%
Recurrent Disease
16%
Red Clover Extract
11%
RNA 16S
13%
Schistosoma
70%
Schistosomiasis
100%
Symptom
83%
Urinary System
70%
Urine Incontinence
12%
Urine Sampling
14%
Keyphrases
Abnormal Blood Vessels
33%
Apical Suspension
33%
Bacterial Vaginosis
33%
Bilharzia
33%
Botulinum
6%
Cervical Lesions
52%
Cervical Pathology
33%
Cervicovaginal
9%
Circulating Anodic Antigen
14%
Clean Catch
19%
Community Workers
8%
Concurrent Surgery
8%
Defect Repair
33%
Dialister
9%
Endemic Countries
12%
Female Genital Schistosomiasis
66%
Fetal Cardiac
33%
Fetal Cardiac Tumor
8%
Fetal Heart Failure
33%
Fluid Milk
8%
Genital
33%
Genital Schistosomiasis
33%
Healthcare Workers
8%
Heart Dysfunction
8%
Male Genital Schistosomiasis
33%
Medical Questionnaires
8%
Midstream Urine
6%
Paravaginal Defect
33%
Patient-provider Agreement
26%
Pelvic Exam
14%
Pelvic Organ Prolapse Quantification (POP-Q)
8%
Phase 2 Randomized Controlled Trial
33%
Porphyromonas
14%
Progressive Resolution
8%
Pubococcygeus muscle
25%
S. Haematobium
8%
Schistosoma
37%
Schistosoma Haematobium
9%
Schistosome Egg
8%
Sexually Transmitted Infections
33%
Southern Africa
33%
Test Agreement
6%
Transplacental
33%
Transplacental Therapy
8%
Tumor Reduction
8%
Urodynamic Study
6%
Urogenital
14%
Vaginal Fluid
8%
Voided Urine
6%
Zambia
33%
Pharmacology, Toxicology and Pharmaceutical Science
Analgesic Agent
5%
Biological Marker
66%
Cohort Study
33%
Disease
24%
Disease Course
33%
Dysbiosis
5%
Fetus Disease
5%
Incontinence
11%
Intestine Flora
16%
Intramuscular Injection
5%
Metabolic Disorder
8%
Microbiome
33%
Microflora
58%
Normal Human
11%
Overactive Bladder
33%
Pain
33%
Placebo
33%
Postoperative Pain
5%
Pregnancy Diabetes Mellitus
33%
Red Clover
33%
Red Clover Extract
11%
RNA 16S
13%
Schistosoma
66%
Schistosoma haematobium
8%
Schistosomiasis
66%
Symptom
22%
Urinary Tract Infection
5%
Urine Incontinence
12%
Vagina Discharge
8%
